May 22, 2025 at 11:00 AM EDT (USA)

Register for Creative Biolabs' Webinar: https://www.creativebiolabs.net/generation-of-a-dual-function-multi-engager-antibody-for-simultaneous-targeting-nk-cells-and-tumor-cells.htm

The relentless pursuit of innovative cancer immunotherapies has unveiled natural killer (NK) cells as formidable agents in the fight against malignancies. While these innate immune cells possess inherent tumor-killing capabilities, their full potential remains constrained by regulatory mechanisms and tumor evasion strategies. At the forefront of this research stands ADAM17, a membrane-associated protease that functions as both a negative regulatory checkpoint in NK cells and a tumor-associated antigen overexpressed in various malignancies. Creative Biolabs is honored to invite Dr. Bruce Walcheck to introduce the Targeted ADAM17 Blocker and Killer (TABK), an ingenious multi-engager antibody complex that simultaneously enhances NK cell proliferation while directing these empowered immune cells to engage and eliminate ADAM17-expressing tumor cells. Join us to explore how this innovative approach leverages ADAM17's unique dual role to create a potent immunotherapeutic strategy with promising implications for cancer treatment.

During this webinar, we will discuss the following key points:

• NK cell-mediated natural cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC)
• Utilizing NK cells to kill cancer cells
• ADAM17, a membrane-associated protease expressed by NK cells
• ADAM17 functions as a negative regulatory checkpoint in NK cells and is a tumor-associated antigen
• ADAM17 inhibition by the mAb Medi-1 enhances NK cells activation and proliferation
• Development of the multi-engager antibody complex Targeted ADAM17 Blocker and Killer (TABK)
• TABK selectively blocks ADAM17 in NK cells and synergizes with IL-15 stimulation to enhance NK cell activation and proliferation
• TABK engages ADAM17 overexpressed by various malignancies, linking NK cells to tumor cells to mediate their killing